can someone point out where i am wrong?, page-7

Moreld,

I read somewhere that Biota will be getting their share of royalties from the Japanese made LANI; Sankyo will be getting their royalties and the profit from making and selling the stuff. Outside Japan the same applies with regards royalties for both parties.
It's a pity Biota doesn't have any manufacturing ambitions, in particular with regards to the HRV antiviral since there is no partner yet and treating the common cold could be big.
I suppose if Biota made too much money they'd have to pay dividends, a skill which board members have shown no aptitude for until now.